Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Hagan-Brown v. Eli Lilly and Company
Case Number:
1:14-cv-01614
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 01, 2015
Eli Lilly Cleared By Jury In Cymbalta Withdrawal Suit
A Virginia federal jury cleared drugmaker Eli Lilly & Co. on Tuesday of allegations it had negligently downplayed the risks of Cymbalta withdrawal in its labeling, shooting down the last claims of a trimmed-down suit from two women who claimed they suffered severe withdrawal symptoms.
-
August 31, 2015
Data Justified Cymbalta Risk Warnings, Eli Lilly Says
An Eli Lilly & Co. official refuted allegations at a Virginia federal jury trial Monday that it hid the withdrawal risks of antidepressant drug Cymbalta, saying the company accurately used data to lay out the risks for doctors in its labeling.
-
August 28, 2015
Fraud Claims Against Lilly Tossed In Cymbalta Labeling Row
A Virginia federal judge on Friday found that two women suing Eli Lilly and Co. for allegedly misrepresenting the withdrawal risks of its antidepressant drug Cymbalta had failed to present enough jury evidence to support their fraud claims, tossing them from court but keeping alive a negligence allegation.
-
August 24, 2015
Eli Lilly Blasted Over Cymbalta Labeling In Side Effect Row
Eli Lilly and Co. downplayed the withdrawal risk of its antidepressant drug Cymbalta to the point of fraud, a pair of women told a Virginia federal jury Monday, saying the company portrayed their symptoms as rare when almost half of the patients experienced similar withdrawal.